Kura Oncology (NASDAQ:KURA) CEO Troy Edward Wilson Purchases 100,000 Shares

Kura Oncology, Inc. (NASDAQ:KURA) CEO Troy Edward Wilson acquired 100,000 shares of the stock in a transaction on Monday, August 17th. The shares were acquired at an average price of $11.12 per share, with a total value of $1,112,000.00. Following the purchase, the chief executive officer owned 379,194 shares in the company, valued at $4,216,637.28. This represents a 35.82% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kura Oncology Stock Performance

Shares of KURA opened at $11.28 on Tuesday. The business’s 50 day moving average is $10.27 and its two-hundred day moving average is $9.36. Kura Oncology, Inc. has a 52-week low of $6.95 and a 52-week high of $12.49. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -3.35 and a beta of 0.38. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. Analysts forecast that Kura Oncology, Inc. will post -3.3 EPS for the current fiscal year.

Analyst Ratings Changes

KURA has been the subject of several recent analyst reports. Oppenheimer set a $24.00 price objective on shares of Kura Oncology in a report on Thursday, May 28th. CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, June 4th. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $25.62.

Hedge Funds Weigh In On Kura Oncology

Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in shares of Kura Oncology during the second quarter valued at approximately $621,000. Corient Private Wealth LP bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $1,344,000. Bank of America Corp DE acquired a new position in Kura Oncology during the 2nd quarter valued at approximately $12,735,000. Man Group plc acquired a new position in Kura Oncology during the 2nd quarter valued at approximately $4,749,000. Finally, Jupiter Topco LLC bought a new position in Kura Oncology during the 2nd quarter worth $273,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.